SUMMARY SHEET

Agenda Nr. 1.05-8.3  |  Subject  |  Progress on Vaccine Development

For Information  |  For Discussion  |  For Decision

Introduction
Research towards development of improved TB vaccines has reached an important watershed, with products from a decade of work in experimental laboratory models entering into clinical testing. In this context, the Working Group on TB Vaccine Development provides a global forum that brings laboratory and clinical researchers together with experts in tuberculosis control and representatives from commercial and non-profit funding agencies to facilitate progress towards the common goal of improved vaccination procedures. The goal of the TB Vaccine Working Group is to have a safe, effective and reasonably priced TB vaccine licensed for global distribution by 2015, and to have the vaccine widely used in TB high-burden countries by 2020.

Summary
The aims of this presentation are:

- To give an overview of the progress achieved in bringing TB vaccine candidates into clinical evaluation;
- To provide insight into the scientific opportunities that will help to keep the TB vaccine development pipeline filled;
- To discuss the vaccine working group's portfolio of facilitating activities
- To outline scientific, programmatic and economic challenges lying ahead and attempt to propose solutions to tackle them.

Decisions requested from the Stop TB Coordinating Board

NONE

Next steps and time frame

<table>
<thead>
<tr>
<th>WHAT</th>
<th>WHO</th>
<th>WHEN</th>
<th>FOCAL POINT</th>
</tr>
</thead>
</table>

8th Stop TB Partnership Coordinating Board Meeting, 3rd - 4th May 2005